TrialSignal
Clinical trial intelligence report
An Open Label, Phase Ib, Dose-escalation Study Evaluating the Safety and Tolerability of Xentuzumab and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumours and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive, HER2-, Breast Cancer, Followed by Expansion Cohorts.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03099174-Jul 28, 2026
NCT ID
NCT03099174
Status
COMPLETED
Phase
Phase 1b
Sponsor
Boehringer Ingelheim
Executive brief
Investment-Ready Snapshot
Boehringer Ingelheim's trial evaluates the combination of Xentuzumab and Abemaciclib in advanced solid tumors, particularly in breast cancer and NSCLC. The focus on hormone receptor-positive breast cancer aligns with a significant market opportunity, given the increasing prevalence of breast cancer and the demand for effective therapies. The competitive landscape includes established CDK4/6 inhibitors like Palbociclib and Ribociclib, necessitating a robust differentiation strategy based on safety and efficacy profiles. Successful outcomes could enhance Boehringer Ingelheim's oncology portfolio and provide leverage in negotiations with payers and healthcare providers.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03099174
Indication
Neoplasms
Modality
small molecule
Target
Xentuzumab targets the insulin-like growth factor 1 receptor (IGF-1R), while Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). The combination aims to inhibit tumor growth in hormone receptor-positive, HER2-negative breast cancer and non-small cell lung cancer (NSCLC).
Intervention
Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant, Abemaciclib
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.